Noetik vs PointClickCare

Side-by-side comparison of AI visibility scores, market position, and capabilities

PointClickCare leads in AI visibility (93 vs 24)
Noetik logo

Noetik

EmergingHealthcare Tech

AI Cancer Biology & Drug Discovery

Noetik raised 2M and signed a 0M GSK licensing deal to build cancer biology foundation models on multi-omic data, uncovering drug targets invisible to conventional tools (2022, SF).

AI VisibilityBeta
Overall Score
D24
Category Rank
#1 of 1
AI Consensus
70%
Trend
up
Per Platform
ChatGPT
20
Perplexity
17
Gemini
18

About

Noetik is a San Francisco-based AI-native biotechnology company founded in 2022 with the mission of decoding cancer biology at molecular resolution using foundation models trained on multi-omic data. The company was founded on the thesis that the biological complexity underlying cancer — the interactions between tumor cells, the immune system, the tumor microenvironment, and genomic variation — exceeds what human researchers or conventional computational tools can fully model, and that large-scale AI trained on comprehensive biological datasets can discover drug targets and patient stratification strategies that would otherwise remain hidden. Noetik builds cancer biology foundation models that learn the language of cellular systems from massive datasets of genomic, transcriptomic, and proteomic measurements.\n\nNoetik's platform applies its foundation models to drug discovery programs, with a focus on identifying novel targets in difficult-to-treat cancers and predicting which patient populations are most likely to respond to specific therapeutic mechanisms. The models are designed to generate hypotheses at a speed and scale that dramatically compresses the early discovery timeline, enabling the company and its partners to explore vastly more biological hypotheses per year than conventional approaches allow. Noetik's scientific platform is built to be partnered as well as proprietary — the company licenses its cancer biology AI capabilities to pharmaceutical companies seeking to accelerate and de-risk their early discovery pipelines.\n\nNoetik has raised $62 million in total funding and secured a $50 million licensing deal with GSK, one of the world's largest pharmaceutical companies, validating both the scientific quality of its foundation models and the commercial interest from major pharma in AI-native biology platforms. The GSK deal provides both capital and a prestigious scientific partnership that elevates Noetik's credibility across the drug discovery ecosystem. As AI biology becomes a defining competitive dimension in pharmaceutical R&D, Noetik's cancer-focused foundation models and demonstrated ability to attract top-tier pharma partnerships position it as an emerging leader in AI-driven oncology drug discovery.

Full profile
PointClickCare logo

PointClickCare

LeaderSenior Care Tech

Long-Term Care Platform

Cloud-based EHR and care coordination platform for long-term and post-acute care organizations. Mississauga, Canada. Raised $172M+, unicorn. Serves 27,000+ care facilities across North America.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 1
AI Consensus
68%
Trend
up
Per Platform
ChatGPT
88
Perplexity
99
Gemini
99

About

PointClickCare is North America's leading cloud-based software platform for the long-term and post-acute care (LTPAC) market, headquartered in Mississauga, Ontario, Canada. Founded in 1999, the company has raised over $172 million and achieved unicorn valuation status. PointClickCare serves over 27,000 care facilities including skilled nursing facilities, senior living communities, assisted living centers, and home health agencies across the United States and Canada. The platform provides electronic health records (EHR), billing, care coordination, and business intelligence capabilities.\n\nPointClickCare's platform is built around the complex clinical and regulatory workflows unique to post-acute care, which differ substantially from acute hospital EHR requirements. The system manages MDS assessments, care planning, medication administration records, therapy documentation, and the complex billing requirements for Medicare, Medicaid, and managed care payers. Its network effect is significant — because PointClickCare connects so many facilities, care transitions between hospitals and post-acute settings can be managed with streamlined data exchange.\n\nThe company has expanded through strategic acquisitions including Collective Medical, which added care transition and high-risk patient identification capabilities powered by a large hospital and payer data network. PointClickCare's Marketplace ecosystem allows third-party technology vendors to integrate with the platform, creating an app store model that extends its functionality without requiring PointClickCare to build every adjacent capability. As value-based care models push accountable care organizations to manage patient outcomes across the full episode of care, PointClickCare's position at the post-acute node of the care continuum becomes increasingly strategically important.

Full profile

AI Visibility Head-to-Head

24
Overall Score
93
#1
Category Rank
#1
70
AI Consensus
68
up
Trend
up
20
ChatGPT
88
17
Perplexity
99
18
Gemini
99
28
Claude
99
15
Grok
91

Key Details

Category
AI Cancer Biology & Drug Discovery
Long-Term Care Platform
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Noetik
AI Cancer Biology & Drug Discovery
Only PointClickCare
Long-Term Care Platform

Integrations

Only PointClickCare

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.